Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC® using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC®, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The approval marks a significant step for Regentis as it scales up production to meet anticipated demand. The solvent-free process not only boosts yield but also enhances safety for workers and the environment, aligning with stricter regulatory standards. According to the company, GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC® is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
The company’s European strategy includes establishing Centers of Excellence and training programs to ensure surgeons are proficient in the GelrinC procedure. Collaborations with institutions like Humanitas Research Hospital are intended to generate real-world evidence and support adoption. The broader U.S. cartilage repair market, valued at approximately $3 billion, represents a substantial opportunity for Regentis as it seeks to bring GelrinC to patients.
For more information, visit the full press release at https://ibn.fm/Ths4h and the company’s newsroom at https://ibn.fm/RGNT.
